Cited by 653Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchMedical Imaging Techniques and Applications

The DOI matches its Crossref record.

Early Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [F-18]-T807

Chien, David T., Bahri, Shadfar, Szardenings, A. Katrin, Walsh, Joseph C., Mu, Fanrong, Su, Min-Ying, Shankle, William R., Elizarov, Arkadij, Kolb, Hartmuth C.·2013·Journal of Alzheimer's Disease

DOI 10.3233/jad-122059

Open this paper in CoChat — free account

Abstract

Aggregates of hyperphosphorylated tau (PHF-tau), such as neurofibrillary tangles, are linked to the degree of cognitive impairment in Alzheimer's disease. We have developed a novel PHF-tau targeting positron emission tomography imaging agent, [F-18]-T807, which may be useful for imaging Alzheimer's disease and other tauopathies. Here in, we describe the first human brain images with [F-18]-T807.

Integrity signals

Registry

Crossref · 10.3233/jad-122059

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Items 401–500 of 653

Graph Models of Pathology Spread in Alzheimer's Disease: An Alternative to Conventional Graph Theoretic Analysis
Raj, A. (2021) · Brain Connectivity · doi:10.1089/brain.2020.0905 · Cited by 21
“…s undergoes hyperphosphorylation (Noble et al., 2013), loses its stabilizing function, mis-sorts into the somatodendritic compartment (Li et al., 2011), and eventually aggregates into neuroﬁbrillary tangles (Chien et al., 2013; Clavaguera et al., 2009; Elobeid et al., 2012; Tai et al., 2014).”
Future Directions in Imaging Neurodegeneration
Masdeu, J. C. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0718-1 · Cited by 22
PET, SPECT, and MRI imaging for evaluation of Parkinson’s disease
Gujral, J. (2024) · American Journal of Nuclear Medicine and Molecular Imaging · doi:10.62347/aicm8774 · Cited by 22
Distinct [18F]THK5351 binding patterns in primary progressive aphasia variants
Schaeverbeke, J. M., Evenepoel, C., Declercq, L., Gabel, S., Meersmans, K., Bruffaerts, R., Adamczuk, K., Dries, E., Bouwel, K. V., Sieben, A., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4075-3 · Cited by 25
“The recent introduction of tau PET ligands, including [(18)F]AV1451 (T807 or flortaucipir) [8] and [(18)F]THK5351 [9], may create the opportunity to measure tauopathy in vivo.”
Background
Alzheimer’s Dementia: The Emerging Role of Positron Emission Tomography
Tripathi, S. M., & Murray, A. D. (2021) · The Neuroscientist · doi:10.1177/1073858421997035 · Cited by 23
Advances in CNS Imaging Agents: Focus on PET and SPECT Tracers in Experimental and Clinical Use
George, N., Gean, E. G., Nandi, A., Фролов, Б. А., Zaidi, E., Lee, H., Brašić, J. R., & Wong, D. F. (2015) · CNS Drugs · doi:10.1007/s40263-015-0237-z · Cited by 21
Cerebral hypometabolism and grey matter density in MAPT intron 10 +3 mutation carriers.
Deters, K., Risacher, S. L., Farlow, M. R., Unverzagt, F. W., Kareken, D. A., Hutchins, G. D., Yoder, K. K., Murrell, J. R., Spina, S., Epperson, F., et al. (2014) · Europe PMC (PubMed Central) · Cited by 20
Characterization of the binding of tau imaging ligands to melanin-containing cells: putative off-target-binding site
Tago, T., Toyohara, J., Harada, R., Furumoto, S., Okamura, N., Kudo, Y., Takahashi‐Fujigasaki, J., Murayama, S., & Ishii, K. (2019) · Annals of Nuclear Medicine · doi:10.1007/s12149-019-01344-x · Cited by 21
New protein deposition tracers in the pipeline
Jovalekic, A., Koglin, N., Mueller, A., & Stephens, A. W. (2016) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-016-0015-3 · Cited by 19
“…2 Characteristics of published tau protein tracers updated from (Villemagne et al. 2015) (Continued) 6,5,6 Tricyclic pyrimidines and indoles [18F]-T807 (Chien et al. 2013; Xia et al. 2013) • Tracer with broadest clinical data package • Cortical retention consistent with the known…”
Background
Update on SPECT and PET in parkinsonism – part 2
Meyer, P. T., Frings, L., & Hellwig, S. (2014) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000107 · Cited by 19
Plasma pTau217 ratio predicts continuous regional brain tau accumulation in amyloid‐positive early Alzheimer's disease
Devanarayan, V., Charil, A., Horie, K., Doherty, T., Llano, D. A., Andreozzi, E., Sachdev, P., Ye, Y., Murali, L. K., Zhou, J., et al. (2025) · Alzheimer's & Dementia · doi:10.1002/alz.14411 · Cited by 19
Imaging Tau Deposits In Vivo: Progress in Viewing More of The Proteopathy Picture
Mathis, C. A., & Klunk, W. E. (2013) · Neuron · doi:10.1016/j.neuron.2013.09.001 · Cited by 18
Compensating for choroid plexus based off-target signal in the hippocampus using 18F-flortaucipir PET
Pawlik, D., Leuzy, A., Strandberg, O. T., & Smith, R. A. (2020) · NeuroImage · doi:10.1016/j.neuroimage.2020.117193 · Cited by 23
PET Neuroimaging in Dementia Conditions
Perani, D., Caminiti, S. P., Carli, G., & Tondo, G. (2020) · Springer eBooks · doi:10.1007/978-3-030-53168-3_9 · Cited by 20
Tracer development for PET imaging of proteinopathies
Kallinen, A., & Kassiou, M. (2022) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2022.04.001 · Cited by 18
PET Imaging in Preclinical Anti-Aβ Drug Development
Syvänen, S., Meier, S. R., Roshanbin, S., Xiong, M., Faresjö, R., Gustavsson, T., Bonvicini, G., Schlein, E., Aguilar, X., Julku, U. H., et al. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03277-z · Cited by 20
Imaging Aβ and tau in early stage Alzheimer’s disease with [18F]AV45 and [18F]AV1451
on behalf of the Deep and Frequent Phenotyping study team, Firouzian, A., Whittington, A., Searle, G. E., Koychev, I. G., Zamboni, G., Lovestone, S., & Gunn, R. N. (2018) · EJNMMI Research · doi:10.1186/s13550-018-0371-y · Cited by 19
Tau PET Imaging
Higuchi, M. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9358-8_18 · Cited by 20
Development of tau PET Imaging Ligands and their Utility in Preclinical and Clinical Studies
Choi, Y., Ha, S., Lee, Y., Kim, Y. K., Lee, D. S., & Kim, D. J. (2017) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-017-0484-7 · Cited by 18
“In comparison of HC, MCI, and AD subjects, retention of (18)F–AV-1451 (T807) increased in medial and inferior temporal gyrus of temporal cortex in AD [47, 52, 54, 55, 59].”
Background
Binding of [18F]AV1451 in post mortem brain slices of semantic variant primary progressive aphasia patients
Schaeverbeke, J. M., Celen, S., Cornelis, J., Ronisz, A., Serdons, K., Laere, K. V., Thal, D. R., Tousseyn, T., Bormans, G. M., & Vandenberghe, R. R. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04631-x · Cited by 19
“These findings are surprising since the vast majority of SV PPA patients have underlying TDP-43 proteinopathy [5] and are not expected to show [(18)F]AV1451 binding in the anterior temporal lobe as the ligand has selectivity for tau over amyloid (29 fold) [7].”
BackgroundInfluential
Deep residual inception encoder‐decoder network for amyloid PET harmonization
Shah, J., Gao, F., Li, B., Ghisays, V., Luo, J., Chen, Y., Lee, W., Zhou, Y., Benzinger, T. L. S., Reiman, E. M., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12564 · Cited by 16
“11 13–16 Human amyloid imaging started more than 15 years ago with the development of Pittsburgh Compound-B (PIB), 17 and has since been widely adopted by many research groups.”
Chronic Traumatic Encephalopathy
Turk, K. W., & Budson, A. E. (2019) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000686 · Cited by 23
Detection of tau in Gerstmann-Sträussler-Scheinker disease (PRNP F198S) by [18F]Flortaucipir PET
Risacher, S. L., Farlow, M. R., Bateman, D. R., Epperson, F., Tallman, E. F., Richardson, R. M., Murrell, J. R., Unverzagt, F. W., Apostolova, L. G., Bonnin, J. M., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0608-z · Cited by 19
The 2024 NIA-AA biological definition of Alzheimer’s disease: linking biomarkers to clinical practice
Kobayashi, G., Hirata, K., Ono, M., Kasuga, K., & Takado, Y. (2026) · Frontiers in Dementia · doi:10.3389/frdem.2026.1736297 · Cited by 21
“Following the success of amyloid PET, tau PET capable of detecting NFTs was developed in 2013, marking another major milestone in AD imaging (Chien et al., 2013; Maruyama et al., 2013).”
Distinct amyloid and tau PET signatures are associated with diverging clinical and imaging trajectories in patients with amnestic syndrome of the hippocampal type
Lagarde, J., Olivieri, P., Tonietto, M., Gervais, P., Comtat, C., Caillé, F., Bottlaender, M., & Sarazin, M. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01628-9 · Cited by 17
The role of neuroimaging in Alzheimer’s disease: implications for the diagnosis, monitoring disease progression, and treatment
Mulumba, J., Duan, R., Luo, B., Wu, J., Sulaiman, M., Wang, F., & Yang, Y. (2025) · Exploration of neuroscience · doi:10.37349/en.2025.100675 · Cited by 23
Positron Emission Tomography Molecular Imaging in Late-Life Depression
Hirao, K., & Smith, G. S. (2014) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988713516540 · Cited by 15
Coordination chemistry of ligands: Insights into the design of amyloid beta/tau-PET imaging probes and nanoparticles-based therapies for Alzheimer’s disease
Selvan, S. T., Ravichandar, R., Ghosh, K. K., Mohan, A., Mahalakshmi, P., Gulyás, B. Z., & Padmanabhan, P. (2020) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2020.213659 · Cited by 16
Effect of Shortening the Scan Duration on Quantitative Accuracy of [18F]Flortaucipir Studies
Tuncel, H., Visser, D., Yaqub, M. M., Timmers, T., Wolters, E. E., Ossenkoppele, R., van der Flier, W. M., van Berckel, B. N. M., Boellaard, R., & Golla, S. S. V. (2021) · Molecular Imaging and Biology · doi:10.1007/s11307-021-01581-5 · Cited by 16
Human Radiation Dosimetry of [18F]AV-1451(T807) to Detect Tau Pathology
Choi, J. Y., Lyoo, C. H., Lee, J., Cho, H., Kim, K. M., Kim, J. S., & Ryu, Y. H. (2016) · Molecular Imaging and Biology · doi:10.1007/s11307-015-0924-7 · Cited by 16
Data Science-Guided Development of Deoxyfluorination Reagents with Enhanced Reactivity, Practicality, and Safety
Ruos, M. E., Romer, N. P., Deichert, J. A., Alabanza, L. M., Gandhi, S. S., Brown, G. Z., Walroth, R. C., Cruz, K., Gosselin, F., Hong, A. Y., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c07548 · Cited by 14
Understanding Biomarkers of Neurodegeneration: Novel approaches to detecting tau pathology
Cook, C. N., Murray, M. E., & Petrucelli, L. (2015) · Nature Medicine · doi:10.1038/nm.3809 · Cited by 15
Comparison Between Brain and Cerebellar Autoradiography Using [18F]Flortaucipir, [18F]MK6240, and [18F]PI2620 in Postmortem Human Brain Tissue
Aliaga, A., Therriault, J., Quispialaya, K. M., Aliaga, A., Hopewell, R., Rahmouni, N., Macedo, A. C., Kunach, P., Soucy, J., Massarweh, G., et al. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.267539 · Cited by 18
“[ 18 F]PI2620 and [ 18 F] ﬂ ortau-cipir were synthesized similarly to previously published methodologies ( 27,28 ).”
Alzheimer′s disease: Unique markers for diagnosis & new treatment modalities
Aggarwal, N. T., Shah, R. C., & Bennett, D. A. (2015) · The Indian Journal of Medical Research · doi:10.4103/0971-5916.169193 · Cited by 19
T807-modified human serum albumin biomimetic nanoparticles for targeted drug delivery across the blood–brain barrier
Gao, C., Gong, W., Yang, M., Chu, X., Wang, Y., Li, Z., Yang, Y., & Gao, C. (2020) · Journal of drug targeting · doi:10.1080/1061186x.2020.1777420 · Cited by 15
Imaging tau pathology in Parkinsonisms
Coakeley, S., & Strafella, A. P. (2017) · npj Parkinson s Disease · doi:10.1038/s41531-017-0023-3 · Cited by 15
“[(18)F]T807 was first tested clinically in 2 AD, 1 MCI, and three healthy controls.(56) All participants underwent a dynamic PET scan from 0–60min following the injection of [(18)F]T807 and a subsequent 80–100min static scan was also acquired.”
BackgroundMethodInfluential
Military Blast Injury and Chronic Neurodegeneration: Research Presentations from the 2015 International State-of-the-Science Meeting
Agoston, D. V., Arun, P., Bellgowan, P. S. F., Broglio, S. P., Cantu, R. C., Cook, D. G., da Silva, U. O., Dickstein, D. L., Elder, G. A., Fudge, E., et al. (2017) · Journal of Neurotrauma · doi:10.1089/neu.2017.5220 · Cited by 15
Myotonic Dystrophy: an RNA Toxic Gain of Function Tauopathy?
Fernández-Gómez, F.-J., Tran, H., Dhaenens, C., Caillet‐Boudin, M., Schraen‐Maschke, S., Blum, D. L., Sablonnière, B., Buée‐Scherrer, V., Buée, L., & Sergeant, N. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9358-8_17 · Cited by 15
Amyloid beta–independent sleep markers associated with early regional tau burden and cortical thinning
Stankeviciute, L. S., Chhatwal, J. P., Levin, R., Pinilla, V., Schultz, A. P., Redline, S. S., Johnson, K. A., Sperling, R. A., Kozhemiako, N., Purcell, S., et al. (2024) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12616 · Cited by 15
“35,36 Regional values for tau PET were calculated based on FreeSurfer-defined cortical ROIs, usingcerebellargrayasareferenceforcalculatingstandardizeduptake value ratios (SUVRs).”
Advances in PET imaging of protein aggregates associated with neurodegenerative disease
Higuchi, M., Tagai, K., Takahata, K., & Endo, H. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01126-2 · Cited by 21
“66,67).”
New PET markers for the diagnosis of dementia
Payoux, P., & Salabert, A. (2017) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000489 · Cited by 14
ELISA Evaluation of Tau Accumulation in the Brains of Patients with Alzheimer Disease
Shinohara, M., Hirokawa, J., Shimodaira, A., Tashiro, Y., Suzuki, K., Gheni, G., Fukumori, A., Matsubara, T., Morishima, M., Saito, Y., et al. (2021) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlab047 · Cited by 16
Determinants of physical activity engagement in older adults
Stojanovic, M., Babulal, G. M., & Head, D. M. (2023) · Journal of Behavioral Medicine · doi:10.1007/s10865-023-00404-y · Cited by 20
Positron emission tomography neuroimaging in neurodegenerative diseases: Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis
Barć, K., & Kuźma‐Kozakiewicz, M. (2019) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.a2019.0013 · Cited by 15
“High T807 binding is present in both MCI and AD patients, and is especially marked in the inferior temporal gyrus where its uptake correlates with MMSE and Clinical Dementia Rating scale sum of boxes (CDR-SOB) [32, 33].”
Background
Ligand and Structure-based Virtual Screening of Lamiaceae Diterpenes with Potential Activity against a Novel Coronavirus (2019-nCoV)
Rodrigues, G. C. S., Maia, M. D. S., de Menezes, R. P. B., et al. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200716114546 · Cited by 14
18F-AV-1451 positron emission tomography in neuropathological substrates of corticobasal syndrome
Goodheart, A. E., Locascio, J. J., Samore, W. R., Collins, J. A., Brickhouse, M. J., Schultz, A. P., Touroutoglou, A., Johnson, K. A., Frosch, M. P., Growdon, J. H., et al. (2020) · Brain · doi:10.1093/brain/awaa383 · Cited by 16
“is (18)F-AV-1451 (also known as flortaucipir) (Chien et al., 2013; Xia et al., 2013).”
Network interdigitations of Tau and amyloid‐beta deposits define cognitive levels in aging
Kim, C. M., Montal, V., Diez, I. P., Orwig, W., Initiative, A. D. N., & Sepulcre, J. (2021) · Human Brain Mapping · doi:10.1002/hbm.25350 · Cited by 13
“…in postmortem autopsies (Braak & Braak, 1991a, 1991b, 1995) as well as in positron emission tomography (PET) imaging studies (Barthel et al., 2011; Chien et al., 2013; Clark et al., 2011; Clark et al., 2012; Johnson et al., 2016; Klunk et al., 2004; Marquié et al., 2015; Pike et al., 2007;…”
DeepPVC: prediction of a partial volume-corrected map for brain positron emission tomography studies via a deep convolutional neural network
Matsubara, K., Ibaraki, M., Kinoshita, T., & Initiative, A. D. N. (2022) · EJNMMI Physics · doi:10.1186/s40658-022-00478-8 · Cited by 14
“Positron emission tomography (PET) has been used to quantify biological processes such as the deposition of amyloid-beta plaques [1–4] and neuro�brillary tangles [5–8] in the cerebral cortex that occur in neurodegenerative disorders, including Alzheimer’s disease (AD).”
Method
Synthesis of carbon-11-labeled isonicotinamides as new potential PET agents for imaging of GSK-3 enzyme in Alzheimer's disease.
Gao, M., Wang, M., & Zheng, Q.-H. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.01.041 · Cited by 10
AD molecular: Imaging tau aggregates with positron emissions tomography
Betthauser, T. J. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.07.007 · Cited by 14
Pick’s Tau Fibril Shows Multiple Distinct PET Probe Binding Sites: Insights from Computational Modelling
Mishra, S. K., Yamaguchi, Y., Higuchi, M., & Sahara, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010349 · Cited by 14
“Assessing Binding Regions and Affinity of PET Tracers to TauPiD by Docking Current tau PET tracers such as [18F]AV-1451 ([18F]flortaucipir), [18F]THK5351, [11C]PBB3, [18F]PM-PBB3 and [18F]MK-6240 (Figure 1A) have been successful in the in vivo evaluation of tau pathology of AD brains [9,11,16,27,28].”
Method
Impact of spill-in counts from off-target regions on [18F]Flortaucipir PET quantification
López‐González, F. J., Costoya‐Sánchez, A., Paredes‐Pacheco, J., Moscoso, A., Silva‐Rodríguez, J., & Aguiar, P. (2022) · NeuroImage · doi:10.1016/j.neuroimage.2022.119396 · Cited by 13
Strategies of positron emission tomography (PET) tracer development for imaging of tau and α-synuclein in neurodegenerative disorders
Mekala, S., Wu, Y., & Li, Y. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00576g · Cited by 13
Monoamine oxidase binding not expected to significantly affect [18F]flortaucipir PET interpretation
Wright, J. P., Goodman, J. R., Lin, Y., Lieberman, B. P., Clemens, J., Gomez, L. F., Liang, Q., Hoye, A. T., Pontecorvo, M. J., & Conway, K. A. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05822-9 · Cited by 13
“[18F]Flortaucipir, which binds to paired helical filament (PHF) tau in NFTs with high affinity [14, 15], became the first PET tracer approved to estimate the density and distribution of tau NFTs.”
Background
Time for tau
Jagust, W. J. (2014) · Brain · doi:10.1093/brain/awu093 · Cited by 13
“Another series of compounds includes the 18F-labelled T807 and T808 (Chien et al., 2013, 2014); these compounds both demonstrate tau binding to Alzheimer’s disease brain tissue without labelling amyloid-b.”
Background
The incubation period of Alzheimer’s disease and the timing of tau versus amyloid misfolding and spreading within the brain
Goudsmit, J. (2016) · European Journal of Epidemiology · doi:10.1007/s10654-016-0144-8 · Cited by 13
“The diagnosis of AD can currently be confirmed post-mortem by immunohistochemistry specific for amyloid and tau, and more recently in living individuals using positron emission tomography (PET) scans with ligands for amyloid [22] and/or tau [23, 24].”
Background
A Closer Look into the Role of Protein Tau in the Identification of Promising Therapeutic Targets for Alzheimer’s Disease
Khan, R. I., Nirzhor, S. S. R., & Rashid, B. (2018) · Brain Sciences · doi:10.3390/brainsci8090162 · Cited by 12
“Two of the well-known, recently developed tau-selective PET tracers are [18F]T807 and [18F]T808 [173,182].”
Background
Tau Aggregation Correlates with Amyloid Deposition in Both Mild Cognitive Impairment and Alzheimer’s Disease Subjects
Dani, M., Wood, M., Mizoguchi, R., Fan, Z., Edginton, T. L., Hinz, R., Win, Z., Brooks, D. J., & Edison, P. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181168 · Cited by 13
“18 F-ﬂutemetamol and 18 F-ﬂorbetapir are amyloid tracers, while 18 F-AV1451 has nanomolar afﬁnity for paired helical ﬁlament-tau [5].”
[18F]-AV-1451 tau PET imaging in Alzheimer’s disease and suspected non-AD tauopathies using a late acquisition time window
Lagarde, J., Olivieri, P., Caillé, F., Gervais, P., Baron, J., Bottlaender, M., & Sarazin, M. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09530-7 · Cited by 13
Tau-PET abnormality as a biomarker for Alzheimer’s disease staging and early detection: a topological perspective
Ding, J., Shen, C., Wang, Z., Yang, Y., Fakhri, G. E., Lu, J., Liang, D., Zheng, H., Zhou, Y., Sun, T., et al. (2023) · Cerebral Cortex · doi:10.1093/cercor/bhad312 · Cited by 13
“Radioactive tracer such as 18 F-flortaucipir (18F-AV-1451) is injected into the vein and binds to specific types of NFT in the brain (Chien et al. 2013; Xia et al. 2013).”
Combining multimodal connectivity information improves modelling of pathology spread in Alzheimer’s disease
Thompson, E., Schroder, A., He, T., Shand, C., Soskic, S., Oxtoby, N. P., Barkhof, F., Alexander, D. C., & Initiative, A. D. N. (2024) · Imaging Neuroscience · doi:10.1162/imag_a_00089 · Cited by 14
“In the past decade, the development of tau PET tracers has facilitated the mapping of this pathology in vivo ( Chien et al., 2013).”
Background
Diagnosis of Alzheimer's disease: Towards accuracy and accessibility
Mu, Y., Chang, K., Chen, Y.-F., Yan, K., Wang, C.-X., & Hua, Q. (1970) · Journal of Biological Methods · doi:10.14440/jbm.2024.412 · Cited by 13
“Currently, 18F-AV-1451 is widely used, and has been shown to possess a high affinity for PHF-tau, but binds poorly with other biomarkers, such as Aβ, argyrophilic grains, and α-synuclein, so it can serve to differentiate AD and other non-AD degenerative diseases [44-45].”
Background
Click Chemistry: The Certainty of Chance (Nobel Lecture)**
Sharpless, K. B., Finn, M. G., & Kolb, H. C. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202501229 · Cited by 12
Self-citation
Neuroimaging Biomarkers in Alzheimer’s Disease
Khan, T. K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-804832-0.00003-1 · Cited by 11
Tau and Amyloid Positron Emission Tomography Imaging Predict Driving Performance Among Older Adults with and without Preclinical Alzheimer’s Disease
Roe, C., Babulal, G., Mishra, S., Gordon, B., Stout, S. H., Ott, B. L., Carr, D., Ances, B., Morris, J., & Benzinger, T. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170521 · Cited by 15
Recent advances in pre-clinical diagnosis of Alzheimer’s disease
Zhou, J., Benoit, M., & Sharoar, M. G. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00733-4 · Cited by 14
“The benzimidazole pyrimidine derivative 18F-flortaucipir exhibits high binding capacity and specificity to tau PHF (Chien et al. 2013).”
BackgroundInfluential
Aluminium co-localises with Biondi ring tangles in Parkinson’s disease and epilepsy
Mold, M. J., & Exley, C. (2022) · Scientific Reports · doi:10.1038/s41598-022-05627-8 · Cited by 12
The Pattern of Brain Amyloid Load in Posterior Cortical Atrophy Using 18F-AV45: Is Amyloid the Principal Actor in the Disease
Beaufils, É., Ribeiro, M. J., Vierron, E., Vercouillie, J., Dufour‐Rainfray, D., Cottier, J., Camus, V., Mondon, K., Guilloteau, D., & Hommet, C. (2014) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000363761 · Cited by 12
18F-Labelled catecholamine type radiopharmaceuticals in the diagnosis of neurodegenerative diseases and neuroendocrine tumours: approaches to synthesis and development prospects
Vatsadze, S. Z., Eremina, O. E., Veselova, I. A., Kalmykov, S. N., & Nenajdenko, V. G. (2017) · Russian Chemical Reviews · doi:10.1070/rcr4752 · Cited by 12
Ice Hockey Summit II
Smith, A. M., Stuart, M. J., Dodick, D. W., Roberts, W. O., Alford, P. W., Ashare, A. B., Aubrey, M., Benson, B. W., Burke, C. J., Dick, R. W., et al. (2015) · Clinical Journal of Sport Medicine · doi:10.1097/jsm.0000000000000195 · Cited by 13
Financial decision-making and capacity in older adults
Marson, D., Kerr, D., & McLaren, D. (2021) · Handbook of the Psychology of Aging · doi:10.1016/b978-0-12-411469-2.00019-4 · Cited by 7
Partial volume correction in longitudinal tau PET studies: is it really needed?
Costoya‐Sánchez, A., Moscoso, A., Sobrino, T., Ruibal, Á., Grothe, M. J., Schöll, M., Silva‐Rodríguez, J., & Aguiar, P. (2024) · NeuroImage · doi:10.1016/j.neuroimage.2024.120537 · Cited by 11
“Among the wide range of tau PET radiotracers available (Gogola et al., 2022; Lemoine et al., 2017), [ 18 F]flortaucipir (FTP) has been the most studied, demonstrating its ability for the in vivo detection and monitoring of AD-related 3R/4R tauopathy (Chien et al., 2013; Leuzy et al., 2019).”
PET Radioligands for Imaging of Tau Pathology: Current Status
Choe, Y. S., & Lee, K.-H. (2015) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-015-0374-9 · Cited by 11
“Furthermore, these radioligands were shown to bind to PHFs of tau in AD brains and their retention was associated with disease severity [59, 61].”
Background
Tau Positron Emission Tomography Imaging in Degenerative Parkinsonisms
Lyoo, C. H., Cho, H., Choi, J. Y., Ryu, Y. H., & Lee, M. S. (2018) · Journal of Movement Disorders · doi:10.14802/jmd.17071 · Cited by 12
Comparing Tau PET Visual Interpretation with Tau PET Quantification, Cerebrospinal Fluid Biomarkers, and Longitudinal Clinical Assessment
Chen, C. D., Ponisio, M. R., Lang, J. A., Flores, S., Schindler, S. E., Fagan, A. M., Morris, J. C., & Benzinger, T. L. S. (2023) · Journal of Alzheimer’s Disease · doi:10.3233/jad-230032 · Cited by 10
Case 9-2015
Miller, B. L., Dickerson, B. C., Lucente, D. E., Larvie, M., & Frosch, M. P. (2015) · New England Journal of Medicine · doi:10.1056/nejmcpc1409839 · Cited by 10
Recent development in selective Tau tracers for PET imaging in the brain
Li, Y., Liu, T., & Cui, M. (2022) · Chinese Chemical Letters · doi:10.1016/j.cclet.2022.03.024 · Cited by 10
Functional Connectivity in Alzheimer’s Disease: Measurement and Meaning
Johnson, K. A., Sperling, R. A., & Sepulcre, J. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.07.010 · Cited by 10
Coevolution of Atomic Resolution and Whole-Brain Imaging for Tau Neurofibrillary Tangles
Dalton, R. M., Krishnan, H. S., Parker, V. S., Catanese, M. C., & Hooker, J. M. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00426 · Cited by 10
Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrumPreprint
Bevan-Jones, W. R., Cope, T., Jones, P. S., Passamonti, L., Hong, Y. T., Fryer, T., Arnold, R., Coles, J., Aigbirhio, F., Larner, A., et al. (2019) · bioRxiv · doi:10.1101/525642 · Cited by 30
Diagnostic and predictive power of plasma proteins in Alzheimer's disease: a cross-sectional and longitudinal study in China
Li, W., Sun, L., Yue, L., & Xiao, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-66195-7 · Cited by 10
Precision neurology
Small, S. L. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102632 · Cited by 10
“Finally, the discovery and approval of the p-tau ligand 18 F-flortaucipir (Chien et al., 2013; Mattay et al., 2020; Schwarz et al., 2016) has significantly advanced in vivo diagnosis and treatment monitoring in AD (Tian et al., 2022; Wang et al., 2024), including staging via the Braak criteria…”
Ice Hockey Summit II
Smith, A. M., Stuart, M. J., Dodick, D. W., Roberts, W. O., Alford, P. W., Ashare, A. B., Aubrey, M., Benson, B. W., Burke, C. J., Dick, R. W., et al. (2015) · Current Sports Medicine Reports · doi:10.1249/jsr.0000000000000132 · Cited by 9
“Noninvasive diagnostic techniques include MRI, DTI, magnetic resonance spectroscopy, and positron emission tomography (PET) using ligands specific for paired helical filament tau (115,116).”
Method
New advances in tau imaging in parkinsonism
Valli, M., & Strafella, A. P. (2017) · International Review of Psychiatry · doi:10.1080/09540261.2017.1396446 · Cited by 9
“This tracer has been used because of its selectivity towards tau over beta-amyloid plaques and its quick uptake and washout capability (Chien et al., 2013; Xia et al., 2013).”
Background
Longitudinal Tau PET Using18F-Flortaucipir: The Effect of Relative Cerebral Blood Flow on Quantitative and Semiquantitative Parameters
Visser, D., Tuncel, H., Ossenkoppele, R., Yaqub, M. M., Wolters, E. E., Timmers, T., Weltings, E., Coomans, E. M., den Hollander, M. E., van der Flier, W. M., et al. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.263926 · Cited by 9
“Several tau PET tracers are available for this purpose, of which (18)F-flortaucipir is the only tau PET tracer approved by the FDA(1-5).”
Background
Discovery and evaluation of aza-fused tricyclic derivatives for detection of Tau pathology in Alzheimer's disease
Liu, T., Li, Y., Wang, Y., Yan, X., Dai, J., & Cui, M. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114991 · Cited by 10
Uptake of AV-1451 in meningiomas
Bruinsma, T. J., Johnson, D. R., Fang, P., Senjem, M. L., Josephs, K. A., Whitwell, J. L., Boeve, B. F., Pandey, M. K., Kantarci, K., Jones, D. T., et al. (2017) · Annals of Nuclear Medicine · doi:10.1007/s12149-017-1205-0 · Cited by 11
Tau Imaging with 18 F-MK6240 across the Alzheimer’s Disease spectrumPreprint
Rowe, C. C., Doré, V., Krishnadas, N., Burnham, S. C., Lamb, F., Mulligan, R. S., Bozinovski, S., Laws, S. M., Tyrrell, R., Huang, K., et al. (2022) · medRxiv · doi:10.1101/2022.02.13.22270894 · Cited by 9
Multimodal investigation of neuropathology and neurometabolites in mild cognitive impairment and late-life depression with 11C-PiB beta-amyloid PET and 7T magnetic resonance spectroscopy
Davies‐Jenkins, C. W., Workman, C. I., Hupfeld, K. E., Zöllner, H. J., Leoutsakos, J., Kraut, M. A., Barker, P. B., Smith, G. S., & Oeltzschner, G. (2024) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2024.06.003 · Cited by 8
Targeting tau in Alzheimer’s Disease: rationale, approach and challenges
Aslanyan, A., Foiani, M. S., Giovannucci, T. A., McDade, E., Duff, K., Mummery, C. J., Schöll, M., Wildsmith, K. R., & Paterson, R. W. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00925-5 · Cited by 10
Recent advances in Alzheimer’s disease: From molecular mechanisms to therapeutic strategies
Rudman, M. D., Ulrich, J. D., & Holtzman, D. M. (2026) · Cell · doi:10.1016/j.cell.2026.06.006 · Cited by 12
Radioactive synthesis of tau PET imaging agent 18F-AV-1451 and its role in monitoring the progression of Alzheimer’s disease and supporting differential diagnosis
Zhang, W., Xu, S., Yu, H., Li, X., Jin, Z., Li, Y., & He, Z. (2021) · Annals of Nuclear Medicine · doi:10.1007/s12149-020-01566-4 · Cited by 8
Preclinical Evaluation of Novel PET Probes for Dementia
Cools, R., Kerkhofs, K., Leitao, R. C. F., & Bormans, G. M. (2023) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2023.03.004 · Cited by 9
Massachusetts Alzheimer's Disease Research Center: Progress and challenges
Hyman, B. T., Growdon, J. H., Albers, M. W., Buckner, R. L., Chhatwal, J. P., Gómez‐Isla, T., Haass, C., Hudry, E., Jack, C. R., Johnson, K. A., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.06.1887 · Cited by 8
“described a work using a newly developed tauPET ligand [(18)F]-T807 [2,3].”
Method
Radiopharmaceuticals for Assessment of Altered Metabolism and Biometal Fluxes in Brain Aging and Alzheimer’s Disease with Positron Emission Tomography
Xie, F., & Peng, F. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170280 · Cited by 8
Synthesis of carbon-11-labeled 5-HT6R antagonists as new candidate PET radioligands for imaging of Alzheimer’s disease
Wang, X., Dong, F., Miao, C., Li, W., Wang, M., Gao, M., Zheng, Q., & Xu, Z. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.04.014 · Cited by 8
Molecular Imaging of Extrapyramidal Movement Disorders With Dementia: The 4R Tauopathies
Frey, K. A. (2021) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.12.003 · Cited by 8
Cognitive Impairment and Dementias.
Khosravi, M., Newberg, A., & Alavi, A. (2018) · Seminars in nuclear medicine · doi:10.1053/j.semnuclmed.2018.07.005 · Cited by 8
Iterative framework for image registration and partial volume correction in brain positron emission tomography
Matsubara, K., Ibaraki, M., Shidahara, M., Kinoshita, T., & Initiative, A. D. N. (2020) · Radiological Physics and Technology · doi:10.1007/s12194-020-00591-2 · Cited by 8
Comprehensive review on design perspective of PET ligands based on β-amyloids, tau and neuroinflammation for diagnostic intervention of Alzheimer’s disease
Mittal, P., Singh, N., Chaturvedi, S., Jyoti, A., Mishra, A. K., & Hazari, P. P. (2021) · Clinical and Translational Imaging · doi:10.1007/s40336-021-00410-7 · Cited by 9
“Kinetic analysis revealed the separation of cerebellum TAC from the elevated cortical regions starting at 30 min post-injection of AD patients [64, 75].”
Background

Authors: Chien, D. T., Bahri, S., Szardenings, A. K., Walsh, J. C., Mu, F., Su, M.-Y., Shankle, W. R., Elizarov, A., & Kolb, H. C.
Affiliations: Siemens Molecular Imaging, Inc., Culver City, CA, USA
University of California, Irvine (US)
Hoag Memorial Hospital Presbyterian (US)
ORCID: Bahri, Shadfar
Szardenings, A. Katrin
Su, Min-Ying
Shankle, William R.
Kolb, Hartmuth C.
Venue: Journal of Alzheimer's Disease
Publisher: SAGE Publications
Published: 2013-06-20
Volume: 34
Issue: 2
Pages: 457-468
ISSN: 1387-2877 (ISSN-L)
1875-8908
DOI: 10.3233/jad-122059
OpenAlex: W4235092975
Cited by: 651
References: 0
Citations by year: 2026: 14 · 2025: 26 · 2024: 19 · 2023: 31 · 2022: 40 · 2021: 51 · 2020: 49 · 2019: 49 · 2018: 57 · 2017: 88 · 2016: 87 · 2015: 62 · 2014: 54 · 2013: 23
FWCI: 52.32
Type: journal article
Language: en
Open access: closed
Locations: Journal of Alzheimer s Disease (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords: PHF-tau
MeSH terms: Aged, Aged, 80 and over, Alzheimer Disease, Carbolines, Female, Fluorine Radioisotopes, Frontal Lobe, Humans, Male, Middle Aged, Phosphorylation, tau Proteins, Early Diagnosis, Positron-Emission Tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Early Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [F-18]-T807

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks